1. Aptamedicine: a new treatment modality in personalized cancer therapy

Somayeh Vandghanooni, Morteza Eskandani, Jaleh Barar , Yadollah Omidi*

Bioimpacts. 2019;9(2): 67-70. doi: 10.15171/bi.2019.09

PMCID: PMC6637218 PMID: 31334037 Scopus ID: 85067455587

Article

PDF

Full Text

XML

Cited By:

Aptamers (Aps) are short single-strand nucleic acids, which can be used as the therapeutic and targeting agent in advanced drug delivery systems. Conjugation of Aps with other entities (siRNA, toxins, drugs, DNAzyme/Ribozymes) provides advanced multifunctional nanosystems for cancer therapy.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons